Tender detail
Non-exclusive rebate agreements for adalimumab medicines under an open-house model
Summary
The procurement concerns non-exclusive rebate agreements for medicines containing the active substance adalimumab (WHO ATC code L04AB04). Agreements are concluded through an open-house model, and demand-dependent quantities are unknown; no minimum purchase quantity is guaranteed. Agreements run no later than 30 June 2028, and the contracting authority may end the procedure earlier.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.